Skip to main content
Clinical Trials/NCT03251131
NCT03251131
Completed
Phase 2

REstricted Fluid Therapy VERsus Standard trEatment in Acute Kidney Injury - REVERSE-AKI Randomized Controlled Pilot Trial

Helsinki University Central Hospital7 sites in 5 countries100 target enrollmentNovember 8, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute Kidney Injury
Sponsor
Helsinki University Central Hospital
Enrollment
100
Locations
7
Primary Endpoint
Cumulative fluid balance
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Observational studies among patients with acute kidney injury (AKI) have shown an association with fluid accumulation and increased mortality. Trials among other subgroups of critically ill patients have demonstrated that restricting fluid input after the initial resuscitation appears safe.

The objective if this study is to determine whether a fluid restrictive treatment regimen will lead to a lower cumulative fluid balance at 72 hours from randomization in critically ill patients with AKI and whether this approach is safe and feasible.

Detailed Description

Acute kidney injury (AKI) is common in the critically ill and associates with adverse outcomes. Patients with AKI are frequently have low urine output and are at high risk of developing fluid overload. Fluid overload has been associated with an increased risk for mortality in such patients. Previous trials in critically ill patients found that a 'restrictive fluid therapy' after resuscitation was safe. Implementing a restrictive fluid therapy approach in patients with AKI may also be of benefit. To date, however, no randomized trial has been performed to evaluate the safety and feasibility of implementing a 'restrictive fluid therapy' approach compared to standard fluid therapy in patients with AKI. In this pilot randomized controlled trial we will evaluate the implementation of a fluid restrictive approach, compared to standard therapy, in adult critically ill patients with acute kidney injury.

Registry
clinicaltrials.gov
Start Date
November 8, 2017
End Date
April 30, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Suvi Vaara

MD, PhD

Helsinki University Central Hospital

Eligibility Criteria

Inclusion Criteria

  • 18-years or older and admitted to critical care with an arterial line in place
  • The patient has been in critical care for at least 12 hours but no more than 72 hours
  • The patient has AKI but is not receiving acute RRT:
  • For the purpose of the study AKI is defined the by the following criteria:
  • Increase in serum creatinine over 1.5-times above baseline without a decline of 27umol/l or more from the last preceding measurement (at least 12 hours apart) AND/OR
  • Overall urine output less than 0.5ml/kg/h (or 6ml/kg) for the previous 12h (with urine catheter in place for the period)
  • The patient is judged by the treating clinician not to be intravascularly hypovolemic
  • The patient is likely to remain in critical care for 48 hours after randomization

Exclusion Criteria

  • Active bleeding necessitating transfusion
  • Maintenance fluid therapy is necessary due to diabetic ketoacidosis, non-ketotic coma, severe burns or other clinical reason determined by the medical staff
  • Need for RRT due to intoxication of a dialyzable toxin
  • Commencement of RRT is expected in the next 6 hours
  • On chronic renal replacement therapy (maintenance dialysis or renal transplant)
  • Presence or a strong clinical suspicion of parenchymal AKI (for example glomerulonephritis, vasculitis, acute interstitial nephritis), or post-renal obstruction
  • Severe hyponatremia (Na \<125mmol/L) or hypernatremia (Na \>155mmol/L)
  • Need for extracorporeal membrane oxygenation or molecular absorbent recirculating system (MARS-therapy)
  • Pregnant or lactating
  • Patients who are not to receive full active treatment

Outcomes

Primary Outcomes

Cumulative fluid balance

Time Frame: 72 hours

Secondary Outcomes

  • Cumulative fluid balance(ICU discharge/ 7 days)
  • Duration of acute kidney injury(ICU discharge/14 days)
  • Cumulative dose of diuretics(ICU discharge/ 7 days)
  • Number of patients requiring renal replacement therapy(14 days)

Study Sites (7)

Loading locations...

Similar Trials